Other Events ·
XORTX Therapeutics terminated its investor relations agreement with IR Agency LLC effective August 7, 2026, rescinding…
XRTXXORTX Therapeutics Inc.
XORTX Therapeutics terminated its investor relations agreement with IR Agency LLC effective August 7, 2026, rescinding a $2.5 million marketing arrangement originally funded by proceeds from a May 19, 2026 public offering. The company returned the full fee to itself on August 14, 2026 and postponed the program while completing its voluntary delisting from the TSX Venture Exchange, expected September 1, 2026. Additionally, Computershare Investor Services Inc. replaces TSX Trust Company as transfer agent effective September 1, 2026. The filing also corrects a prior omission by disclosing $240,000 in aggregate cash finder’s fees paid for the April 13, 2026 acquisition of Vectus Biosystems Limited’s Renal Anti-Fibrotic Therapeutic Program. XORTX is a late-stage clinical pharmaceutical company developing therapies for gout and progressive kidney disease.